Qiagen has agreed to a $191 million deal to acquire STAT-Dx. The takeover will give Qiagen control of a pipeline of assay panels designed to diagnose infections affecting the respiratory and gastrointestinal systems.
SUBSCRIBE
Biohealth Innovation
Founding Member of
